Tag: patents

PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx^® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Beam Global, (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced a 21% increase in energy storage solutions (ESS) revenue in the first half of 2025 vs. 2024. Additionally, a purchase order was received from one of its largest ESS customers, for approximately $2 million, scheduled to be recognized as revenue by the end of 2025. The surge reflects Beam Global’s growing role as a trusted ESS supplier for mission-critical energy storage applications and the Company views repeat customers purchasing in increasing volumes as a strong validation of the reliability of its products.

New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing

MISSISSAUGA, Ontario, July 23, 2025 (GLOBE NEWSWIRE) -- Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), is pleased to announce that it is entering into a loan agreement with certain existing directors and officers of the Company (the “Lenders”) providing for the advance of an unsecured loan (the “Loan”) bearing interest at 5.0% per annum in the principal amount of $530,000. The Loan shall mature on the date that is one year from the advance of the Loan (the “Maturity Date”).   In conjunction with the advance of the Loan, the Company will also pay a set-up fee of $20,000 to the Lenders.

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: